Literature DB >> 24635692

Lessons learned from our elders: how to study polypharmacy in populations with intellectual and developmental disabilities.

Jessica N Stortz, Johanna K Lake, Virginie Cobigo, Hélène M J Ouellette-Kuntz, Yona Lunsky.   

Abstract

Polypharmacy is the concurrent use of multiple medications, including both psychotropic and non-psychotropic drugs. Although it may sometimes be clinically indicated, polypharmacy can have a number of negative consequences, including medication nonadherence, adverse drug reactions, and undesirable drug-drug interactions. The objective of this paper was to gain a better understanding of how to study polypharmacy among people with intellectual and developmental disabilities (IDD). To do this, we reviewed literature on polypharmacy among the elderly and people with IDD to inform future research approaches and methods on polypharmacy in people with IDD. Results identified significant variability in methods used to study polypharmacy, including definitions of polypharmacy, samples studied, analytic strategies, and variables included in the analyses. Four valuable methodological lessons to strengthen future polypharmacy research in individuals with IDD emerged. These included the use of consistent definitions of polypharmacy, the implementation of population-based sampling strategies, the development of clinical guidelines, and the importance of studying associated variables.

Entities:  

Mesh:

Year:  2014        PMID: 24635692     DOI: 10.1352/1934-9556-52.1.60

Source DB:  PubMed          Journal:  Intellect Dev Disabil        ISSN: 1934-9491


  7 in total

Review 1.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

2.  Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.

Authors:  Maria G Valdovinos; Meara Henninger-McMahon; Elizabeth Schieber; Lisa Beard; Brenna Conley; Annette Haas
Journal:  Int J Dev Disabil       Date:  2016-04-28

3.  Changes in community and hospital-based health care use during the COVID-19 pandemic for adults with and without intellectual and developmental disabilities.

Authors:  A Durbin; R Balogh; E Lin; L Palma; L Plumptre; Y Lunsky
Journal:  J Intellect Disabil Res       Date:  2022-03-30

4.  Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.

Authors:  Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2020-11-23       Impact factor: 5.321

5.  Effectiveness of medication reviews in identifying and reducing medication-related problems among people with intellectual disabilities: A systematic review.

Authors:  Amal Nabhanizadeh; Alyt Oppewal; Fleur Heleen Boot; Dederieke Maes-Festen
Journal:  J Appl Res Intellect Disabil       Date:  2019-02-22

6.  Psychotropic Medication Monitoring in a Human Services Organization for Children with Autism Spectrum Disorder: Description and Evaluation of Interdisciplinary Team Review.

Authors:  Frank Bird; Jill M Harper; James K Luiselli; Andrew Shlesinger; Joseph Gold
Journal:  Behav Anal Pract       Date:  2022-03-25

7.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.